Skip to content
Catalyst

PapersPMID:31343402

Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.

Health technology assessment (Winchester, England)2019The record ↗

  1. Finding, very limited evidenceno difference foundForced expiratory volume in one second (FEV1)

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact.”
    Study
    RCT
    Duration
    12 months
    Dose studied
    200 mg once or twice a day, determined by ideal body weight and smoking status
    Population
    Adults with COPD (FEV1/FVC < 0.7) at high risk of exacerbation, on a drug regimen including inhaled corticosteroids in both arms, with two or more treated exacerbations in the previous year

Study record

Design
randomised controlled trial
Species
human
Population
People with COPD currently on a drug regimen including inhaled corticosteroids with a history of two or more exacerbations treated with antibiotics and/or oral corticosteroids in the previous year
Participants
1,578
Comparator
placebo
Duration
365 days
Endpoints measured
9